

Re-irradiation of recurrent glioblastoma using helical TomoTherapy with simultaneous integrated boost: preliminary considerations of treatment efficacy

Donatella Arpa^{1,*}, Elisabetta Parisi¹, Giulia Ghigi¹, Alessandro Savini², Sarah Pia Colangione¹, Luca Tontini¹, Martina Pieri¹, Flavia Foca³, Rolando Polico¹, Anna Tesei⁴, Anna Sarnelli² & Antonino Romeo¹

¹Radiotherapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. ²Medical Physics Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. ³Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. ⁴Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

Supplementary Table S1. Detailed patient characteristics

| Surgery at initial diagnosis | MGMT methylation status | Adjuvant treatment | Adjuvant TMZ | Salvage treatment before HT-SIB | Interval between first RT and HT-SIB (months) | Therapy at PD after HT-SIB | PFS after HT-SIB (months) | OS after HT-SIB (months) | OS after initial diagnosis (months) |
|------------------------------|-------------------------|--------------------|--------------|---------------------------------|---|----------------------------|---------------------------|--------------------------|-------------------------------------|
| GTR | Unknown | RT/TMZ | TMZ | Re-surgery | 17 | Fotemustine | 6 | 8 | 26 |
| GTR | Unknown | RT/TMZ | - | Re-surgery | 44 | Unknown | 20 | 88.5 | 135 |
| GTR | Unmethylated | RT/TMZ | - | Re-surgery | 10 | BSC | 2 | 7 | 27 |
| STR | Unmethylated | RT/TMZ | TMZ | - | 9 | BSC | 7 | 7 | 19 |
| STR | Unmethylated | RT/TMZ | TMZ | - | 4 | Fotemustine | 2 | 4 | 11 |
| STR | Unknown | RT/TMZ | TMZ | - | 29 | BSC | 1.6 | 1.6 | 32 |
| STR | Methylated | RT/TMZ | TMZ | Re-surgery | 33 | Second Re-RT | 6 | 13 | 47 |
| GTR | Methylated | RT/TMZ | TMZ | - | 13 | BSC | 4 | 4 | 20 |
| BIOPSY | Methylated | RT/TMZ | TMZ | Fotemustine | 34 | Rechallenge TMZ | 2 | 10 | 44 |
| STR | Unmethylated | RT/TMZ | TMZ | Bevacizumab | 9 | BSC | 2 | 11 | 23 |
| STR | Methylated | RT/TMZ | TMZ | Re-surgery | 13 | BSC | 2 | 4 | 19 |
| STR | Unmethylated | RT/TMZ | TMZ | Re-surgery | 31 | Etoposide+ carboplatin | 4 | 16 | 48 |
| GTR | Unmethylated | RT/TMZ | TMZ | Re-Surgery | 8 | Fotemustine | 6 | 7 | 18 |
| GTR | Methylated | RT/TMZ | TMZ | Bevacizumab | 35 | BSC | 2 | 4 | 25 |
| GTR | Methylated | RT/TMZ | TMZ | - | 60 | Re-surgery followed by TMZ | 24 | 36 | 98 |
| GTR | Unmethylated | RT/TMZ | TMZ | Fotemustine | 13 | PCV | 6 | 9 | 25 |
| GTR | Methylated | RT/TMZ | TMZ | - | 33 | TMZ | 8 | 11 | 47 |
| GTR | Methylated | RT/TMZ | TMZ | - | 11 | Bevacizumab | 4 | 7 | 22 |
| GTR | Methylated | RT/TMZ | TMZ | - | 9 | PCV | 4 | 28 | 40 |
| GTR | Unknown | RT/TMZ | TMZ | - | 65 | Unknown | 10 | 14 | 81 |
| STR | Unmethylated | RT/TMZ | TMZ | Fotemustine | 41 | Bevacizumab | 2 | 7 | 50 |
| GTR | Methylated | RT/TMZ | TMZ | Re-surgery | 46 | Fotemustine | 2 | 8 | 58 |
| STR | Unknown | RT/TMZ | TMZ | Re-surgery | 19 | Bevacizumab | 16 | 18 | 40 |
| STR | Methylated | RT/TMZ | TMZ | - | 21 | Bevacizumab | 4 | 27 | 51 |

GTR: gross total resection; STR: subtotal resection; TMZ: temozolomide; BSC: best supportive care; HT-SIB: helical TomoTherapy-simultaneous integrated boost; Re-RT: re-irradiation; PCV: procarbazine, lomustine and vincristine.